Antiverse, a Welsh techbio company specializing in antibody design for challenging drug targets, has announced it has secured $9.3 million in new investment capital. This funding round marks a significant milestone for the company, which focuses on creating new enabling technologies to bring novel therapies to patients and change lives.
Headquartered in Cardiff, UK, with additional offices in Boston, MA, Antiverse develops de novo antibody therapeutics. The company leverages state-of-the-art machine learning techniques combined with advanced cell line engineering to address difficult drug targets such as GPCRs and ion channels. This integrated approach aims to overcome limitations in traditional antibody discovery, accelerating the development of treatments for conditions that are currently underserved by existing therapies.
The newly raised capital will be strategically deployed to accelerate Antiverse's research and development initiatives and expand its operational footprint. The company plans to significantly grow its scientific and engineering teams, further enhance its proprietary AI-driven antibody design platform, and advance its pipeline of therapeutic candidates. This substantial investment underscores investor confidence in Antiverse's innovative methodology and its potential to significantly impact the biopharmaceutical landscape by addressing complex disease targets.
Looking ahead, Antiverse is focused on scaling its operations and broadening its therapeutic applications. The company aims to continue its mission of developing transformative antibody therapies, ultimately bringing new solutions to patients and changing lives through its advanced technological capabilities and expanded research efforts.
